Oral L-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats

Chem Biol Interact. 2013 Apr 25;203(2):530-41. doi: 10.1016/j.cbi.2013.02.006. Epub 2013 Mar 4.

Abstract

L-glutamine is a non-essential amino acid. It decreased blood sugar, stimulated insulin secretion in type 2 diabetic patients. The objective of the present investigation was to evaluate L-glutamine increases glucagon like peptide-1 (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats. Molecular docking study was performed to elucidate the molecular basis for GLP-1 receptor agonistic activity. Type 2 diabetes was induced in overnight fasted Sprague Dawley rats pre-treated with nicotinamide (100 mg/kg, i.p.) followed by 20 min after administration of streptozotocin (55 mg/kg, i.p.). The rats were divided into; I - nondiabetic, II - diabetic control, III - sitagliptin (5 mg/kg, p.o.), IV - L-glutamine (250 mg/kg, p.o.), V - L-glutamine (500 mg/kg, p.o.) and VI - L-glutamine (1000 mg/kg, p.o.). The L-glutamine and sitagliptin treatment was 8 week. Plasma glucose was estimated every week. Body weight, food and water intake were recorded daily. Glycosylated haemoglobin, lipid profile, plasma and colonic active (GLP-1) (7-36) amide, mRNA expression of proglucagon GLP-1, plasma and pancreatic insulin, histology of pancreata and biomarkers of oxidative stress (superoxidase dismutase, reduced glutathione, malondialdehyde, glutathione peroxidase, glutathione S transferase) were measured after 8 week. In acute study, the rats were divided into I - glucose (2.5 g/kg, p.o.), II - sitagliptin (5 mg/kg, p.o.), III - L-glutamine (250 mg/kg, p.o.), IV - L-glutamine (500 mg/kg, p.o.) and V - L-glutamine (1000 mg/kg, p.o.). Plasma glucose, active GLP-1 (7-36) amide concentration and insulin levels were measured after glucose loading. The docking data indicated that l-glutamine bind to the GLP-1 receptor. L-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.

MeSH terms

  • Administration, Oral
  • Animals
  • Blood Glucose / metabolism*
  • Body Weight / drug effects
  • Colon / drug effects
  • Colon / metabolism
  • Diabetes Mellitus, Experimental / blood*
  • Diabetes Mellitus, Experimental / metabolism*
  • Diabetes Mellitus, Experimental / physiopathology
  • Drinking / drug effects
  • Gene Expression Regulation / drug effects
  • Glucagon-Like Peptide 1 / blood
  • Glucagon-Like Peptide 1 / genetics
  • Glucagon-Like Peptide 1 / metabolism*
  • Glucagon-Like Peptide-1 Receptor
  • Glucose Tolerance Test
  • Glutamine / administration & dosage*
  • Glutamine / metabolism
  • Glutamine / pharmacology*
  • Glycated Hemoglobin / metabolism
  • Insulin / blood
  • Insulin / metabolism
  • Lipid Metabolism / drug effects
  • Male
  • Molecular Docking Simulation
  • Niacinamide / adverse effects*
  • Oxidative Stress / drug effects
  • Pancreas / drug effects
  • Pancreas / metabolism
  • Pancreas / pathology
  • Peptide Fragments / blood
  • Peptide Fragments / genetics
  • Peptide Fragments / metabolism*
  • Protein Conformation
  • Pyrazines / administration & dosage
  • Pyrazines / metabolism
  • Pyrazines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Glucagon / chemistry
  • Receptors, Glucagon / metabolism
  • Sitagliptin Phosphate
  • Triazoles / administration & dosage
  • Triazoles / metabolism
  • Triazoles / pharmacology

Substances

  • Blood Glucose
  • Glp1r protein, rat
  • Glucagon-Like Peptide-1 Receptor
  • Glycated Hemoglobin A
  • Insulin
  • Peptide Fragments
  • Pyrazines
  • Receptors, Glucagon
  • Triazoles
  • Glutamine
  • glucagon-like peptide 1 (7-36)amide
  • Niacinamide
  • Glucagon-Like Peptide 1
  • Sitagliptin Phosphate